OP White Papers - random

  1. Establishing Commercial Manufacturing Services For ADCs 6/3/2024

    Explore how one organization built upon 15+ years of experience and an extensive knowledge base of biologics manufacturing to establish commercial-scale ADC manufacturing capabilities.

  2. Unlocking The Potential Of Biocatalysis 1/22/2026

    Biocatalysis delivers cleaner, more selective pharma processes while cutting energy use and waste. Engineered enzymes broaden their reach, enabling faster development and greater sustainability.

  3. Onshoring Advantage: 7 Forces Reshaping Global Biologics Manufacturing 10/27/2025

    Policy, trade, and security pressures are fundamentally reshaping global biologics manufacturing. Forward-looking companies are onshoring critical programs to mitigate risks to supply chains, IP, and regulatory timelines.

  4. Advancing ADCs With Expertise In Payloads And Linkers 2/18/2026

    Discover how integrated containment, high-potency expertise, advanced chromatography, and proven linker–payload process optimization can accelerate your ADC program from early development to reliable commercial supply.

  5. Small Molecule API Production: Unveiling The Impact Of Fermentation 5/16/2024

    Technological developments have led to growth in the suitability of fermentation for a myriad of applications. Explore the impact of the evolution of synthetic biology and supporting technologies on modern fermentation practice.

  6. Modernizing Clinical Trial Logistics To Deliver Value 2/3/2026

    Explore how biopharma organizations can design and operate clinical supply systems that absorb complexity while maintaining control and consistency.

  7. Liposomal And Nanoparticle Technology 9/3/2025

    Specializing in oncology, anti-infective, and complex formulations, Pfizer Melbourne provides manufacturing services for sterile dosage forms.

  8. Designing, Selecting, And Developing Bioconjugates For Clinical Success 10/24/2024

    Accelerate the development of complex bioconjugates to unlock new possibilities for targeted therapies and advance the next generation of precision medicine.

  9. Accelerated API Manufacturing: Combining All Process Development Stages 5/16/2024

    During early-stage development, utilize the key considerations outlined in this paper to avoid common pitfalls and expedite the transition from molecule to market.

  10. AAV-Based Gene Editing For Huntington's Disease 10/28/2025

    LETI-101 uses AAV5 to deliver a compact CRISPR system for allele-selective editing of mutant HTT, showing promise as a one-time treatment for Huntington’s disease with strong preclinical safety and efficacy.